News
Semaglutide 1 mg improves walking distance in patients with early peripheral artery disease and type 2 diabetes, regardless ...
In a surprising shift from its original purpose, Ozempic, a widely used weight loss drug —is now being linked to heart protection. Researchers have found that semaglutide, the drug’s active ...
1d
MedPage Today on MSNGLP-1 Drugs Can Be Used First for Weight Loss, Says American College of CardiologyWith semaglutide and tirzepatide dosed once weekly, their estimated average yearly costs in the U.S. are $14,080 and $8,126, ...
Study comparing bariatric surgery to GLP-1 medications shows 24% total weight loss from surgery versus 4.7% from injectables, with many patients quitting GLP-1 treatment within a year.
As more people resort to a new generation of drugs to achieve the perfect body, Leah Hardy examines the latest warnings over ...
Novo Nordisk’s campaign, which aims to speak ‘without filters’ by declaring obesity a disease, has been strongly criticized on social media: ‘It’s indecent’ ...
Semaglutide appears to reduce the risk of death, heart attack and stroke in adults with type 2 diabetes more effectively than ...
In the context of new anti-obesity medications, the American College of Cardiology has issued a Scientific Statement updating ...
2d
HealthDay on MSNSemaglutide Offers Cardiovascular Edge Over Empagliflozin in Type 2 DiabetesFor patients aged 45 years or older with type 2 diabetes, semaglutide seems to confer some advantage over empagliflozin in ...
International researchers studied data from 7,899 patients treated with semaglutide and 7,899 treated with empagliflozin to look for differences in the risk of death, heart attack, stroke ...
The American College of Cardiology has issued new guidelines recommending weight management medications as first-line ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results